Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$11.56 -0.7%	$13.64	$7.07 ▼ $15.43	$674.46M	1.45	505,337 shs	341,706 shs
INVVY Indivior	$21.85 -1.8%	$21.85	$14.76 ▼ $35.50	$3.01B	0.35	3,825 shs	8,100 shs
PRVB Provention Bio	$24.98 +3.1%	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	9.12 million shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
VRCA Verrica Pharmaceuticals	$6.90 -2.3%	$5.67	$2.86 ▼ $7.76	$299.48M	1.88	172,796 shs	202,527 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	-0.69%	-8.90%	-17.31%	-2.45%	+38.28%
INVVY Indivior	0.00%	0.00%	0.00%	0.00%	+2.08%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	+2.21%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
VRCA Verrica Pharmaceuticals	-2.27%	-2.40%	+45.57%	+16.75%	+9.35%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EOLS Evolus	4.1661 of 5 stars	3.5	3.0	0.0	3.5	3.2	2.5	0.6
INVVY Indivior	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	3.4982 of 5 stars	3.5	1.0	0.0	4.7	0.6	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	3.00	Buy	$20.60	78.20% Upside
INVVY Indivior	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	3.00	Buy	$11.25	63.04% Upside

Current Analyst Ratings

Latest EOLS, REPH, VRCA, INVVY, and PRVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
4/10/2024	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
3/1/2024	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
3/1/2024	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
3/1/2024	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
1/29/2024	EOLS Evolus	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$10.00 ➝ $16.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$202.09M	3.31	N/A	N/A	($0.36) per share	-32.11
INVVY Indivior	$791M	3.81	$1.15 per share	18.94	$1.45 per share	15.07
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
VRCA Verrica Pharmaceuticals	$5.12M	57.17	N/A	N/A	$0.47 per share	14.68

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$61.69M	-$1.09	N/A	N/A	N/A	-30.52%	N/A	-32.19%	5/14/2024 (Estimated)
INVVY Indivior	$205M	$1.05	20.81	12.00	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
VRCA Verrica Pharmaceuticals	-$67M	-$1.46	N/A	N/A	N/A	-1,307.47%	-119.46%	-70.35%	5/14/2024 (Estimated)

Latest EOLS, REPH, VRCA, INVVY, and PRVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	EOLS Evolus	-$0.15	-$0.20	-$0.05	-$0.19	$61.14 million	$61.00 million
2/29/2024	Q4 2023	VRCA Verrica Pharmaceuticals	-$0.47	-$0.48	-$0.01	-$0.43	$1.10 million	$1.99 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
INVVY Indivior	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	N/A	2.33	2.10
INVVY Indivior	N/A	N/A	N/A
PRVB Provention Bio	0.19	1.93	1.92
REPH Recro Pharma	2.27	3.24	2.74
VRCA Verrica Pharmaceuticals	2.22	4.55	4.49

Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
INVVY Indivior	0.05%
PRVB Provention Bio	37.39%
REPH Recro Pharma	62.34%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.40%
INVVY Indivior	N/A
PRVB Provention Bio	13.10%
REPH Recro Pharma	14.20%
VRCA Verrica Pharmaceuticals	41.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	273	57.94 million	54.82 million	Optionable
INVVY Indivior	800	137.88 million	N/A	Not Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
VRCA Verrica Pharmaceuticals	100	42.42 million	24.82 million	Optionable

EOLS, REPH, VRCA, INVVY, and PRVB Headlines

Source	Headline
	Verrica Pharmaceuticals (NASDAQ:VRCA) Given "Buy" Rating at Needham & Company LLC americanbankingnews.com - April 11 at 5:14 AM
	Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) marketbeat.com - April 10 at 8:24 AM
	Verrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conference msn.com - April 4 at 11:15 AM
	Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss finance.yahoo.com - April 3 at 8:23 AM
	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference globenewswire.com - April 2 at 7:30 AM
	Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection msn.com - March 31 at 11:37 AM
	Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA finanznachrichten.de - March 28 at 3:45 PM
	Verrica Pharma gains as FDA lists Ycanth in Orange Book msn.com - March 27 at 3:42 AM
	Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts markets.businessinsider.com - March 26 at 8:15 AM
	Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA globenewswire.com - March 26 at 7:30 AM
	Verrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chat msn.com - March 3 at 10:22 PM
	Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line finance.yahoo.com - March 2 at 10:39 AM
	When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable? finance.yahoo.com - March 2 at 10:39 AM
	Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results finanznachrichten.de - March 1 at 11:46 PM
	Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating markets.businessinsider.com - March 1 at 6:46 PM
	Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion markets.businessinsider.com - March 1 at 6:46 PM
	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 1 at 1:45 PM
	Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance markets.businessinsider.com - February 29 at 10:09 PM
	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results finance.yahoo.com - February 29 at 12:07 PM
	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results globenewswire.com - February 29 at 7:30 AM
	Earnings Outlook For Verrica Pharmaceuticals benzinga.com - February 28 at 6:01 PM
	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference globenewswire.com - February 27 at 7:30 AM
	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 finance.yahoo.com - February 22 at 10:58 AM
	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 globenewswire.com - February 22 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Evolus

NASDAQ:EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Indivior

OTCMKTS:INVVY

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Provention Bio

NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Verrica Pharmaceuticals

NASDAQ:VRCA

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial